Maxacalcitol - Chugai Pharmaceutical
Alternative Names: 22-oxacalcitriol; OCT; OxarolLatest Information Update: 05 Nov 2023
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Maruho
- Class Antipsoriatics; Calcium regulators; Dihydroxycholecalciferols; Skin disorder therapies
- Mechanism of Action Vitamin D3 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ichthyosis; Palmoplantar keratoderma; Palmoplantar pustulosis; Psoriasis; Secondary hyperparathyroidism
Most Recent Events
- 01 Dec 2019 Chugai Pharmaceutical completes transfer of rights for maxacalcitol to Maruho in Japan
- 30 Jan 2019 Chugai Pharmaceutical plans to transfer rights for Maxacalcitol to Maruho from December 1, 2019
- 28 Jan 2019 No recent reports of development identified for phase-I development in Secondary-hyperparathyroidism(In volunteers) in Taiwan (IV, Injection)